title: Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.
abstract: OBJECTIVE
  To compare foot length deficits between patients with Laron syndrome (LS) (primary growth hormone [GH] insensitivity) and congenital isolated GH deficiency (IGHD) and their response to replacement therapy with insulin-like growth factor-I (IGF-I) and hGH, respectively.
  
  
  METHODS
  Data for the study were collected from the records of nine children with LS (3 M, 6 F) 7.8 +/- 4.8 years old (mean +/- SD), and nine children with IGHD (3 M, 6 F), 3.8 +/- 3.3 years old. Fifteen non-treated adult patients with LS were also included in the study.
  
  
  METHODS
  Measurements of foot length were recorded without treatment and monitored during 9 years of treatment in the children and in the untreated adult patients. For statistical analysis the non-parametric Mann-Whitney U test was used.
  
  
  RESULTS
  With almost similar basal values in growth deficit and pre-treatment growth velocities, the achievements towards norms after 9 years of treatment were greater in the patients with IGHD than in the patients with LS: foot length reached -1.4 +/- 0.8 vs. -3.3 +/- 1.0 SDS (mean +/- SD), and body height -2.2 +/- 1.0 vs. -3.9 +/- 0.5 SDS. The difference between the two groups could be due to the initiation of replacement therapy in the patients with IGHD at a younger age. Adult foot size of untreated patients with LS is small but less retarded than the height deficit.
  
  
  CONCLUSIONS
  Both IGF-I and hGH are potent growth stimulating hormones of linear growth and acrae as exemplified by foot growth.
authors.affiliation: Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva.
authors.forename: Aviva
authors.initials: A
authors.lastname: Silbergeld
authors.forename: Pearl
authors.initials: P
authors.lastname: Lilos
authors.forename: Zvi
authors.initials: Z
authors.lastname: Laron
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001827:Body Height / Q000187:drug effects; D002648:Child; D004393:Dwarfism, Pituitary / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005528:Foot / Q000254:growth & development*; D013006:Growth Hormone / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D046150:Laron Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone